



VITAL CARE RX

Tailored Therapy, Trusted Care

GI Enrollment Form

Phone: (877)229-1724 | Fax: (877)229-1725

PATIENT INFORMATION

(Complete the following or send patient demographic sheet.)

Please fax copy of patient's insurance card including both sides

Name: _____

DOB: _____ Gender: M / F Height: _____ Wt: _____

Address: _____

City, State, Zip: _____

Home Phone: _____

Alternate Phone: _____

Last 4 digits SS#: _____ Email: _____

PRESCRIBER INFORMATION

Prescriber Name: _____

State Lic. #: _____ NPI: _____

Facility Name: _____

Address: _____

City, State, Zip: _____

Phone: _____ Fax: _____

Contact: _____

Phone: _____ Email: _____

CLINICAL INFORMATION – STATEMENT OF MEDICAL NECESSITY

☐ K50.90 Crohn's disease NOS ☐ K51.90 Ulcerative Colitis ☐ Other: _____

Please indicate current or previous treatments and treatment duration below:

☐ NSAIDS Duration: _____

☐ Methotrexate Duration: _____

☐ Sulfasalazine Duration: _____

☐ 6 – MP Duration: _____

☐ Corticosteroids Duration: _____

☐ Azathioprine Duration: _____

☐ 5 – ASA Duration: _____

☐ Other: _____ Duration: _____

Other medications patient is currently taking: _____

TB/PPD Test given? ☐ Yes ☐ No Date: _____ Results: _____ Allergies: _____

BSA: _____

Expected date of first/next dose: _____ Date of last dose: _____

PRESCRIPTION INFORMATION

Medication	Directions	Quantity	Refills
Cimzia® <input type="checkbox"/> Starter Kit <input type="checkbox"/> Prefilled Syringe <input type="checkbox"/> Lyophilized Powder	<input type="checkbox"/> Initial dose: Inject 400 mg SC at week 0, week 2, and week 4 <input type="checkbox"/> Maintenance dose: Inject 400 mg SC every 4 weeks	1 starter kit	0
		28 day supply	
Entyvio® <input type="checkbox"/> 300 mg vial	<input type="checkbox"/> Initial Dose: Infuse 300mg IV over 30 minutes at week 0, week 2 and week 6 <input type="checkbox"/> Maintenance dose: Infuse 300mg IV over 30 minutes every 8 weeks	Initial dose	
		QS	
Humira® <input type="checkbox"/> Starter Kit <input type="checkbox"/> 40 mg Pen <input type="checkbox"/> 40 mg PFS <input type="checkbox"/> Starter Kit CF <input type="checkbox"/> 40 mg CF Pen <input type="checkbox"/> 40 mg CF Prefilled Syringe	<input type="checkbox"/> Initial Dose: Inject 160 mg SC on day 1, 80 mg on day 15, then 40 mg thereafter beginning on day 29 <input type="checkbox"/> Inject 40 mg SC every other week <input type="checkbox"/> Inject 40 mg SC once a week	1 starter kit	0
		28 day supply	
Remicade® <input type="checkbox"/> 100 mg vial	<input type="checkbox"/> Initial Dose: Infuse _____ mg/kg (_____ mg) IV at weeks 0, 2, and 6 weeks. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg (_____ mg) IV every _____ weeks.	QS	
Simponi® <input type="checkbox"/> 100 mg SmartJect <input type="checkbox"/> 100 mg Prefilled Syringe	<input type="checkbox"/> Initial Dose: Inject 200mg SC at week 0, then 100mg at week 2, then maintenance dose <input type="checkbox"/> Maintenance Dose: Inject 100mg SC once every 4 weeks	3 units	0
		28 day supply	
Stelara® <input type="checkbox"/> 130 mg vial	Initial Dose: Infuse IV over at least 1 hour. <input type="checkbox"/> ≤ 121 lbs 260 mg (2 vials) <input type="checkbox"/> > 121 lbs to 187 lbs 390 mg (3 vials) <input type="checkbox"/> > 187 lbs 520 mg (4 vials)	QS	0
		QS	
Xeljanz® <input type="checkbox"/> 5 mg tabs <input type="checkbox"/> 10 mg tabs	<input type="checkbox"/> Initial Dose: Take 10 mg PO BID for 8 weeks <input type="checkbox"/> Maintenance Dose: Take 5 mg PO BID <input type="checkbox"/> Maintenance Dose: Take 10 mg PO BID		
Xifaxan® <input type="checkbox"/> 550mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth 3 times a day	42	0
Other:			

Ship Medications To: ☐ Physician's Clinic ☐ Patient's Home

Injection Training Needed: ☐ Yes ☐ No

Prescriber Signature _____ Date _____ Brand Name Required? ☐ Yes

I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms, financial treatment and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of this product to another pharmacy of the patient's choice or in the patient's insurer's provider network.